Chinese Medical Journal (Jul 2022)
Clinical evaluation of the first domestically produced generic isosulfan blue injection in sentinel lymph node biopsy for early breast cancer in China: a multicenter, single-arm, open validation trial (CSBrS-024)
Abstract
No abstracts available.